Clinical trial
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of…
NCT00040157 · Alexion Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00040157 |
|---|---|
| Title | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. |
| Official title | A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | ACH126-443 (Beta-L-Fd4C) |
| Enrollment | 60 |
| Completion | May 1, 2003 |
| First posted | Jun 25, 2002 |
| Last update posted | Dec 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: